The trial is designed to evaluate PD-02's potential to slow the progression of Parkinson's disease. PD-02 is Avicena's proprietary therapeutic that has demonstrated the potential to improve neurological function in patients with ALS, Huntington's disease, and Parkinson's disease.
In preclinical studies, PD-02 has demonstrated significant neuroprotective properties including protection of the dopaminergic cells which are affected in Parkinson's disease.
As part of its ongoing collaboration with the National Institute of Neurological Disorders and Stroke (NINDS), Avicena will provide PD-02 for the trial and fund a related chronic toxicology study. In turn, Avicena has the right to utilize the study's findings for the new drug application submission to the FDA for the approval of PD-02.